Artelo Biosciences enters glaucoma market via funded study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength
March 25, 2026 7:31 AM EDTThree clinical programs, one core molecule, and a capital-efficient strategy position Artelo Biosciences for sustained growth beyond a single indication
BRISTOL, Tenn., March 25, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) is drawing increased attention following its expansion into the $16.3 billion glaucoma market through a fully funded investigator-sponsored clinical studyan announcement that underscores a broader story: a multi-platform biotech pipeline built for durability across several high-value therapeutic areas.
Artelo Biosciences is running three distinct clinical-stage programs in oncology support, neuropathic pain, and CNS disorders while simultaneously expanding its lead compound into... More
